Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.
about
Mapping biological behaviors by application of longer-lived positron emitting radionuclidesDevelopment of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumabp-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imagingChromatographic separation of selenium and arsenic: A potential (72)Se/(72)As generator.Standardized methods for the production of high specific-activity zirconium-89.A New Synthesis of TE2A-a Potential Bifunctional Chelator for (64)Cu.Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibodyPET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinomaRational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV)PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.Immuno-PET imaging of tumor endothelial marker 8 (TEM8)Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry.86Y based PET radiopharmaceuticals: radiochemistry and biological applicationsModular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry.PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography.Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncologyComparison of cell-labeling methods with ¹²⁴I-FIAU and ⁶⁴Cu-PTSM for cell tracking using chronic myelogenous leukemia cells expressing HSV1-tk and firefly luciferase.Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments.Chromatographic separation of germanium and arsenic for the production of high purity (77)As.Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.Approaches using molecular imaging technology -- use of PET in clinical microdose studies.Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.Unconventional nuclides for radiopharmaceuticalsA practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Promising bifunctional chelators for copper 64-PET imaging: practical (64)Cu radiolabeling and high in vitro and in vivo complex stability.Siderophores for molecular imaging applications.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and TherapyImmuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.Bisphosphonates as radionuclide carriers for imaging or systemic therapy.PET tracers based on Zirconium-89.PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.(89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges.Engineered antibodies for molecular imaging of cancer.ImmunoPET Imaging of αvβ6 Expression Using an Engineered Anti-αvβ6 Cys-diabody Site-Specifically Radiolabeled with Cu-64: Considerations for Optimal Imaging with Antibody Fragments.
P2860
Q26824070-05D8DF0E-99FA-4270-BC3D-254C72D58845Q30525314-A3BD144E-CAEB-4C4A-891E-AA123E9DDA5EQ33527397-49FCEE5B-8E91-4FD8-8778-5B0E41DB87E9Q33629386-6B35E763-01FB-49F1-8E35-4C95B43A01A6Q33647373-137E85D6-FC35-4034-9159-1063CA3FC08AQ33685309-5EB3B456-43B8-45D6-B9B8-CE39C432973DQ33704117-B519B54C-3CEA-4372-B2D8-9C225973980AQ33738280-DD182229-1315-4F28-AB12-E550BDD664A9Q33939881-5083477E-657A-4C9F-A4A7-532F90E8758DQ33943630-D2E70228-AC30-4CB2-8E83-F627D7332482Q34009558-A904F6F2-2B95-4D12-9EF9-E54C8A0D32B8Q34126406-C08EF872-0DDD-427E-B8AE-79C5E5B677E2Q34473434-34AA3EF2-8A23-4905-81F9-BCE6E12B6763Q34724473-E65683F6-26DD-4C0D-AB7D-B173FC0EBCB1Q35250409-0D705E16-14F7-4550-B1F3-85B1D12E3BE4Q35394166-2FB4BAA8-90C4-432A-95D3-A9A5F7BE111DQ35655093-A224E9BB-6D35-4952-9B1F-F67D5F403134Q35736289-AA24AD55-B507-4865-82F3-FD708F14CD98Q36339722-1FF0A92E-26C3-4A52-B8E9-76F2986FA072Q36451125-E999A6C7-40A7-4361-8873-EE2635574961Q36557471-C6C1EE74-75DD-4361-9B97-E90433D1ABBCQ36717182-15EE177C-1553-4C5B-A03A-639BC4D98233Q36799494-8A89253D-525E-4804-9CBB-23E662F5C971Q36953094-384FBCD3-61C7-4F1C-955F-89A1FB2BBD01Q37019430-DF8876A9-C92D-425A-8127-06DF83D14979Q37026964-C12224AD-28C4-4F94-A9BE-2D9CEC938454Q37129181-1DDF45B5-7411-45BE-90D5-20E6C65C1867Q37172093-68290F10-1253-4A9D-985E-1D9687313A25Q37424123-D58FB77A-3C04-4635-A2C4-D6090D7C20C8Q37609134-FF6B2F46-DE26-4CE0-B451-54F5166A1F6EQ37689802-0234D9C1-7525-41D0-A22A-EE42EF82B97FQ37696629-80C61E66-E33D-427D-85C1-11A5021F21B2Q37698959-CECB4980-88A6-460A-ACC4-DA4A4A2F971BQ37869905-332B4A2C-16A5-4740-B304-96400C8BA2E2Q37924117-CE93E709-CA11-4E35-8412-DB8DD18D9681Q37970745-98388BAD-8935-4951-8EA8-3BA515FBB795Q37978157-3683490E-8AE9-4F12-9A6D-8A0969214792Q38111973-BB60C10D-CF4B-405C-916C-DA5E5277EACFQ38148881-2526453C-22B4-4BB9-85B2-0E74A841FC55Q38666311-BE5E61C4-64C9-4709-8BBF-17217C0869C7
P2860
Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Radioimmunoimaging with longer ...... es: potentials and challenges.
@ast
Radioimmunoimaging with longer ...... es: potentials and challenges.
@en
type
label
Radioimmunoimaging with longer ...... es: potentials and challenges.
@ast
Radioimmunoimaging with longer ...... es: potentials and challenges.
@en
prefLabel
Radioimmunoimaging with longer ...... es: potentials and challenges.
@ast
Radioimmunoimaging with longer ...... es: potentials and challenges.
@en
P2860
P356
P1476
Radioimmunoimaging with longer ...... des: potentials and challenges
@en
P2093
Martin W Brechbiel
P2860
P304
P356
10.1021/BC800299F
P577
2009-05-01T00:00:00Z